- Home
- Software Solutions
- Resources
- Corporate
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600EBRAF Mutation
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 22 | |
Additional information about NCT01474551.